Study guide
6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications
Key Takeaways Explain This Topic AI
Systemic menopausal hormone therapy (MHT) is FDA-approved and clinically indicated for moderate-to-severe vasomotor symptoms, prevention of postmenopausal osteoporosis in high-risk individuals, and management of hypoestrogenism in premature menopause or POI until age ~51.
The Timing Hypothesis establishes that initiating MHT within 10 years of menopause or before age 60 provides a favorable benefit-risk profile, lowering all-cause mortality and coronary heart disease, whereas late initiation (>10-20 years post-menopause or age >=60) increases risks of stroke and venous thromboembolism.
Transdermal 17-beta estradiol bypasses hepatic first-pass metabolism, does not increase clotting factors or sex hormone-binding globulin (SHBG), and carries minimal or no increased risk of venous thromboembolism (VTE) or ischemic stroke compared to oral formulations.
Endometrial protection is mandatory in all women with an intact uterus using systemic estrogen, requiring an adequate progestogen (e.g., micronized progesterone 100 mg daily or 200 mg cyclic x 12-14 days/month, or a 52-mg LNG-IUS) to prevent endometrial hyperplasia and adenocarcinoma.
Fezolinetant is a selective oral neurokinin 3 (NK3) receptor antagonist FDA-approved for moderate-to-severe vasomotor symptoms; it carries a boxed warning for liver injury and requires hepatic tests at baseline, monthly for 3 months, and at 6 and 9 months.
Last updated: October 2026
Indications for Systemic Menopausal Hormone Therapy (MHT)
Menopausal Hormone Therapy (MHT) is the most effective evidence-based pharmacotherapy for menopausal symptoms. Guidelines from The Menopause Society and ACOG establish four primary systemic indications:
Bothersome Vasomotor Symptoms (VMS): Systemic estrogen reduces hot flash frequency by ~75% and severity by ~87%, simultaneously improving sleep fragmentation, mood, and quality of life.
Prevention of Postmenopausal Osteoporosis: Estrogen decreases fractures across all skeletal sites by 30% to 40%. It is indicated for fracture prevention in at-risk women under age 60 or within 10 years of menopause.
Hypoestrogenism in Premature Menopause / POI: Women experiencing premature menopause or POI before age 40 face accelerated cardiovascular, bone, and neurocognitive morbidity. Systemic MHT at replacement doses is strongly recommended until at least the median age of natural menopause (~51 years).
Genitourinary Syndrome of Menopause (GSM): Treats vulvovaginal atrophy when present alongside systemic VMS; if GSM occurs in isolation, local vaginal estrogen is preferred.
The "Timing Hypothesis" & The Window of Opportunity
Clinical trials (including WHI sub-analyses, ELITE, and KEEPS) demonstrate that the benefit-to-risk balance of MHT depends on patient age and time elapsed since menopause:
Clinical Parameter Initiation <60 Years Old or <10 Years Post-Menopause Initiation ≥60 Years Old or ≥10–20 Years Post-Menopause
Coronary Heart Disease Decreased coronary calcification; reduced coronary heart disease events and mortality (RR ~0.70–0.80). Increased coronary events via destabilization of existing fibroatheromatous plaques.
Ischemic Stroke Low baseline absolute stroke risk; neutral or minimal excess events. Statistically significant increase in absolute stroke incidence.
Venous Thromboembolism Low absolute risk, particularly when using transdermal estradiol. Substantially elevated absolute VTE and pulmonary embolism risk with oral regimens.
All-Cause Mortality Significant reduction in all-cause mortality (RR ~0.70–0.85). Neutral or slightly increased all-cause mortality.
Clinical Recommendation Favorable benefit-risk profile; optimal window for initiation. Unfavorable benefit-risk balance; initiation generally not recommended.
Note
In November 2025 the FDA began removing the boxed warnings about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy labels; the first six products were relabeled on February 12, 2026. The boxed warning about endometrial cancer with unopposed systemic estrogen in a patient with a uterus remains.
Estrogen Regimens & Delivery Routes: Oral vs. Transdermal
Selecting the route of estrogen administration is vital to optimizing cardiovascular and metabolic safety.
Oral Estrogens
Oral formulations include micronized 17-beta estradiol (0.5–2.0 mg daily) and conjugated equine estrogens (CEE 0.3–0.625 mg daily). Oral intake undergoes hepatic first-pass metabolism , inducing several adverse biochemical pathways:
Prothrombotic Coagulation Factors: Upregulates prothrombin, factors VII and VIII, and prothrombin fragments, while decreasing antithrombin III, causing a 2- to 4-fold increase in venous thromboembolism (VTE) and stroke.
Sex Hormone-Binding Globulin (SHBG): Hepatic induction raises SHBG, reducing circulating free androgens and potentially worsening libido.
Inflammatory & Lipid Markers: Elevates serum triglycerides and high-sensitivity C-reactive protein (hs-CRP).
Transdermal Estrogens
Transdermal formulations (patches 0.025–0.1 mg/day, gels, sprays) deliver bioidentical 17-beta estradiol directly into systemic circulation, completely bypassing hepatic first-pass transit .
Coagulation Neutrality: Does not induce prothrombotic clotting factors; conveys neutral or non-significant excess risks of VTE and ischemic stroke.
Metabolic Stability: Preserves baseline levels of triglycerides, hs-CRP, and SHBG.
Preferred Candidates: First-line choice for women with hypertension, obesity (BMI ≥30 kg/m²), hypertriglyceridemia, controlled diabetes, smoking history, or gallbladder disease .
Essential Endometrial Protection: Regimens & Formulations
Unopposed systemic estrogen drives continuous endometrial epithelial proliferation, inducing glandular atypia, hyperplasia, and a 4- to 8-fold increase in endometrial adenocarcinoma within 3 to 5 years.
Important
Mandatory Rule: Any woman with an intact uterus receiving systemic estrogen MUST receive concurrent progestogen therapy to ensure complete endometrial protection. Estrogen monotherapy is strictly contraindicated with an intact uterus and reserved solely for patients post-hysterectomy.
Progestogen Regimens
Continuous-Combined Regimen: Daily estrogen with daily oral micronized progesterone (100 mg) or medroxyprogesterone acetate (MPA 2.5 mg). Induces endometrial atrophy and amenorrhea (following initial transient spotting).
Cyclic (Sequential) Regimen: Daily estrogen with oral micronized progesterone (200 mg) or MPA (5–10 mg) taken for 12 to 14 consecutive days each month . Induces predictable scheduled withdrawal bleeding; optimal for perimenopausal women with irregular spontaneous menses.
Levonorgestrel Intrauterine System (52-mg LNG-IUS): Delivers potent local endometrial suppression with negligible systemic absorption, concurrently providing contraception during perimenopause.
Micronized Progesterone Benefits: Chemically identical to endogenous progesterone; conveys a lower association with breast cancer and fewer adverse mood/lipid effects than synthetic progestins (such as MPA).
Absolute Contraindications to MHT
Clinicians must screen for absolute contraindications before initiating MHT:
Unexplained, undiagnosed abnormal vaginal bleeding (requires endometrial biopsy and transvaginal ultrasound to rule out malignancy first).
Known, suspected, or history of breast cancer or other estrogen-dependent malignancies.
Active or documented history of arterial thromboembolic disease (myocardial infarction, ischemic stroke, TIA).
Active deep vein thrombosis (DVT) or pulmonary embolism (PE) , or unprovoked VTE history.
Active liver disease , acute liver injury, or significant chronic hepatic impairment.
Known high-risk thrombophilia (homozygous Factor V Leiden, antiphospholipid syndrome).
Known or suspected pregnancy .
Non-Hormonal Pharmacotherapy for Vasomotor Symptoms
Indicated for women with contraindications to estrogen (e.g., breast cancer survivors, thromboembolic history) or those declining hormones.
Fezolinetant (Veozah)
Mechanism: Selective oral neurokinin 3 (NK3) receptor antagonist (45 mg once daily) that blocks neurokinin B on hypothalamic KNDy neurons, restoring thermoregulatory balance without hormonal or tissue-proliferative effects.
Hepatic Monitoring: Serum transaminase elevations occur in 2% to 3% of patients. A December 2024 boxed warning for rare serious liver injury requires baseline hepatic tests (ALT, AST, alkaline phosphatase, bilirubin), then testing monthly for the first 3 months and at 6 and 9 months ; stop the drug if signs of liver injury appear.
Contraindications: Severe renal impairment (eGFR <30 mL/min/1.73 m²), cirrhosis, or concomitant use of moderate/strong CYP1A2 inhibitors (ciprofloxacin, fluvoxamine).
Elinzanetant (Lynkuet)
Dual neurokinin-1/neurokinin-3 receptor antagonist approved by the FDA on October 24, 2025 for moderate-to-severe menopausal hot flashes. The dose is 120 mg (two 60 mg capsules) once daily at bedtime; sleepiness and fatigue are the main adverse effects, so counsel about driving and alcohol.
Centrally Acting Agents
SSRIs and SNRIs: Paroxetine mesylate (7.5 mg daily; FDA-approved for VMS), venlafaxine XR (37.5–75 mg daily), desvenlafaxine (100 mg daily), and escitalopram (10–20 mg daily).
Tamoxifen Drug Interaction: Paroxetine and fluoxetine are potent CYP2D6 inhibitors that block the bioactivation of tamoxifen into its active metabolite, endoxifen , increasing cancer recurrence. Venlafaxine or gabapentin is preferred in patients taking tamoxifen because neither significantly inhibits CYP2D6.
Gabapentin: Alpha-2-delta calcium channel ligand (300–900 mg at bedtime); ideal for nocturnal hot flashes with sleep disruption.
Clonidine: Alpha-2 adrenergic agonist (0.05–0.1 mg daily); modest efficacy, limited by dry mouth, hypotension, and sedation.